Erythropoietin prevents necrotizing enterocolitis in very preterm infants: a randomized controlled trial

Yong Wang¹, Juan Song¹, Huiqing Sun², Falin Xu¹, Kenan Li¹, Chunxia Nie³, Xiaoli Zhang¹, Xirui Peng¹, Lei Xia¹, Ziyun Shen⁴, Xiao Yuan¹, Shan Zhang¹, Xue Ding¹, Yaodong Zhang², Wenqing Kang², Liling Qian⁵, Wenhao Zhou⁵, Xiaoyang Wang¹,⁶, Xiuyong Cheng⁴ and Changlian Zhu¹,⁷,⁸*

Abstract

Background: Necrotizing enterocolitis (NEC) is one of the most severe complications in very preterm infants, but there are currently no accepted methods to prevent NEC. Studies have shown that erythropoietin (EPO) has the potential to prevent NEC or improve outcomes of preterm NEC. This study aimed to determine whether recombinant human EPO (rhEPO) could protect against NEC in very preterm infants.

Methods: The study was a prospective randomized clinical trial performed among four NICU centers. A total of 1327 preterm infants with gestational age ≤32 weeks were admitted to the centers, and 42 infants were excluded leaving 1285 eligible infants to be randomized to the rhEPO or control group. Infants in the rhEPO group were given 500 IU/kg rhEPO intravenously every other day for 2 weeks, while the control group was given the same volume of saline. The primary outcome was the incidence of NEC in very preterm infants at 36 weeks of corrected gestational age.

Results: A total of 1285 infants were analyzed at 36 weeks of corrected age for the incidence of NEC. rhEPO treatment significantly decreased the incidence of NEC (stage I, II and III) (12.0% vs. 17.1%, \( p = 0.010 \)), especially confirmed NEC (stage II and III) (3.0% vs. 5.4%, \( p = 0.027 \)). Meanwhile, rhEPO treatment significantly reduced the number of red blood cells transfusion in the confirmed NEC cases (1.2 ± 0.4 vs. 2.7 ± 1.0, \( p = 0.004 \)). Subgroup analyses showed that rhEPO treatment significantly decreased the incidence of confirmed NEC at gestational age < 28 weeks (\( p = 0.019 \)), and the incidence of all stages NEC in preterm infants with hemoglobin < 90 g/l (\( p = 0.000 \)) and 5 min Apgar score > 5 (\( p = 0.028 \)).

Conclusion: Repeated low-dose rhEPO treatment is beneficial against NEC in very preterm infants.

Trial registration The protocol was registered retrospectively at ClinicalTrials.gov (NCT03919500) on April 18, 2019. https://clinicaltrials.gov/ct2/show/NCT03919500

Keywords: Preterm infant, Necrotizing enterocolitis, Erythropoietin

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
risk for poor long-term growth and neurodevelopmental disorders [3]. Despite preventive strategies including antenatal corticosteroid administration [4], breast milk feeding [5], probiotics [6], and lactoferrin supplementation [7], surgical treatment is still often inevitable. Therefore, strategies specifically for preventing and treating NEC are needed.

Recombinant human erythropoietin (rhEPO) is routinely used as an anti-anemia treatment in preterm infants in the NICU, and it also functions as an anti-inflammatory, antitoxin, and antioxidant [8]. Studies have reported that EPO treatment decreases the incidence and severity of experimental NEC in animal models [9–11], and a retrospective analysis showed that rhEPO (200 IU/kg intravenously with continuous infusion for 2 weeks starting on the first day of life, or 400 IU/kg subcutaneously three times a week) protected against NEC in very low birth weight infants [12]. Lower complication rates and reduced mortality were observed in NEC neonates receiving repeated low-dose rhEPO (200 IU/kg, intramuscular injection, twice a week for a total of 1 week) [13]. Enteral administration of rhEPO (88 IU/kg once daily until the enteral intake reached 100 ml/kg of milk, or after a maximum of 7 days) also decreased the risk of NEC in preterm neonates [14]. However, the optimum dose and timing of rhEPO treatment for NEC in very preterm infants is still uncertain and it could be varied personally because many factors can influence pharmacokinetics of rhEPO [15–17]. Our previous randomized controlled trial showed that repeated-dose rhEPO (500 IU/kg every other day for 2 weeks starting within 72 h after birth) promoted good long-term neurological outcomes in very preterm infants and also showed a protective tendency against NEC [18], but the total number of patients was not enough for accurately evaluating the effect of rhEPO against NEC. Thus, the aim of this study was to further investigate the effect of repeated low-dose rhEPO on NEC in very preterm infants.

**Methods**

**Study design and participants**

This was a prospective randomized clinical trial conducted in four NICU centers, including the Third Affiliated Hospital, Children's Hospital, the First Affiliated Hospital of Zhengzhou University, and the Women and Children Health Care Center of Luoyang. Between January 2014 and June 2017, preterm infants with gestational age ≤32 weeks and hospitalized within 72 h after birth were deemed eligible for the study. Infants with genetic or metabolic diseases, congenital abnormalities, polycythemia, pneumothorax, grade III/IV intracranial hemorrhage, or unstable vital signs (such as respiration and circulation failure) before randomization were excluded from the study. Clinical information and complications were collected during hospitalization. Echocardiography and head ultrasound were examined routinely for all the infants, and hematological parameters were monitored every week. Anemia was defined as hemoglobin (Hb) ≤110 g/L and red blood cell (RBC) transfusions were given for the infants with severe or moderate anemia with severe clinical manifestations [19]. Thrombocytopenia was defined as a platelet count of less than 100 × 10^9/l [20], small for gestational age was defined as birth weight less than the 10th percentile for gestational age, and patent ductus arteriosus was defined as requiring pharmacological therapy or surgical ligation. All survivors were followed up for the incidence of NEC until 36 weeks of corrected gestational age. Written informed consent was obtained from the parents of all included infants. The trial is registered at ClinicalTrials (NCT03919500).

**Randomization and blinding**

The preterm infants were randomly assigned to the rhEPO or control group by the trial investigators in a 1:1 allocation using a simple randomization plan by a computer-based random-number generator in each NICU center. The doctors and nurses in the NICU were aware of the patient treatment groups. The investigators performing quality control, data collection, and analysis were blinded to the treatment groups.

**Intervention**

Infants in the rhEPO group were given rhEPO (500 IU/kg dissolved in 2 ml saline, intravenously once every other day for 2 weeks for a cumulative dose of 3500 IU/kg) starting within 72 h after birth. Infants in the control group were given saline with the same volume and timing. Other treatment and care of preterm infants followed the same routines in all four NICU centers. If the infants developed polycythemia, hypertension, thrombosis, shock, or any other emergency conditions, the rhEPO administration would be stopped immediately and appropriate emergency treatment would be given.

**Outcome**

The primary outcome was the incidence of NEC in very preterm infants at 36 weeks of corrected gestational age. Clinical information, including gestational age, birth weight, sex, prenatal high-risk history, birth history, and complications during hospitalization, was collected by the investigators. Infants with suspected NEC (stage I), moderate NEC (stage II), or severe NEC (stage III) were categorized according to Bell's classification standard [21]. In this study, confirmed NEC was defined as NEC stage II and III. Fulminant NEC was defined as NEC with
rapid clinical progression with death or severe disease requiring surgical management occurring within 48 h of the onset of symptoms [22].

Statistical analysis
Data were analyzed using SPSS 23.0 software (IBM, Armonk, NY). Student’s t-test and the chi-square test were used for baseline analysis. The chi-square test was used for group and subgroup analyses, and the Mantel–Haenszel test was used for interaction analyses in subgroups. A two-tailed \( p \)-value less than 0.05 was deemed significant.

The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Zhengzhou University and Henan Medical Academy (201201002). The sample size was estimated based on the assumption that 12% of the very preterm infants in the NICU would develop confirmed NEC [23]. If the relative risk were to be decreased by 40% with rhEPO treatment, then 591 patients would need to be recruited for each group for a significance level of 5% with 80% power.

Results
Study population and baseline information
Between January 2014 and June 2017, a total of 1327 preterm infants with gestational age \( \leq \) 32 weeks admitted to the four NICU centers were eligible. A total of 42 infants (3 with congenital megacolon, 3 with 21-trisomy, 3 with methylmalonic acidemia, 20 whose parents refused participation, and 13 who died within 72 h) were excluded, and 1285 infants were randomized to the rhEPO (641 infants) and control (644 infants) treatment groups. At 36 weeks of corrected gestational age (Fig. 1), a total 1285 infants were analyzed, and 84 infants died (35 died from respiratory failure, 34 died from sepsis, 8 died from pulmonary hemorrhage, 4 died from NEC, and 3 died from severe brain injury). There were no infants who developed polycythemia, hypertension, thrombosis, or emergency conditions in the rhEPO treatment group. There were no significant differences between the two groups for any of the baseline parameters (\( p > 0.05 \)) (Table 1).

rhEPO treatment decreased the incidence of NEC in very preterm infants
A total of 51 infants (3.8%) of the 1285 very preterm infants developed confirmed NEC (Stage II and III). rhEPO treatment reduced the incidence of NEC (stage I, II and III) (17.1% vs. 12.0%, \( p = 0.010 \) and confirmed
NEC (stage II and III) (5.4% vs. 3.0%, \( p = 0.027 \)) compared to controls. However, rhEPO did not have a significant effect on NEC stage I (11.6% vs. 9.2%, \( p > 0.05 \)), NEC stage II (3.9% vs. 2.3%, \( p > 0.05 \)), or NEC stage III (1.6% vs. 0.6%, \( p > 0.05 \)) (Table 2), or on fulminant NEC [5/110 (4.5%) in controls and 3/77 (3.9%) in the rhEPO group, \( p = 1.000 \)].

No side effects were observed with rhEPO treatment. The average time to develop NEC was 11.9 ± 11.4 days after birth with a mean corrected gestational age of 31.4 ± 2.1 weeks. There was no significant effect on the time to develop NEC after birth (12.6 ± 11.5 days in control group vs. 10.7 ± 11.3 days in the rhEPO group, \( p = 0.555 \)) or on the corrected gestational age at which NEC developed (31.4 ± 1.9 weeks in the control group vs. 31.5 ± 2.6 weeks in the rhEPO group, \( p = 0.864 \)) (Table 3).

**Subgroup analysis of the effect of rhEPO on NEC in very preterm infants**

There was no interaction effect of rhEPO against NEC (all stages) according to gestation age, birth weight, delivery mode, gender, mechanical ventilation, or 1 min Apgar score (interaction \( p > 0.05 \)). However, rhEPO treatment significantly decreased the incidence of all stages NEC in preterm infants with Hb < 90 g/l (\( p < 0.0001 \), interaction \( p = 0.006 \)) and with 5 min Apgar score > 5 (\( p = 0.028 \), interaction \( p = 0.012 \)) (Table 4).

Further analysis showed that the incidence of anemia before being diagnosed with NEC was no different between the control (24/35, 68.6%) and rhEPO (11/19, 57.9%, \( p = 0.553 \)) groups. The ratio of packed RBC

---

**Table 1 Baseline information of very preterm infants**

|                        | Control n = 644 | rhEPO n = 641 | \( p \)-value | Total n = 1285 |
|------------------------|-----------------|---------------|--------------|--------------|
| Gestation age (weeks), median (quartile range) | 30.0 (29.0–31.0) | 29.7 (28.9–30.9) | 0.138 | 29.9 (29.0–30.9) |
| Birth weight (g), median (quartile range)      | 1300 (1100–1450) | 1250 (1100–1410) | 0.131 | 1300 (1100–1450) |
| Small for gestational age (%)                  | 132/644 (20.5)  | 149/641 (23.2)  | 0.228 | 281/1285 (21.9) |
| Male (%)                                          | 385/644 (59.8)  | 374/641 (58.3)  | 0.601 | 759/1285 (59.1) |
| Severe asphyxia (%)                              | 30/644 (4.7)    | 24/641 (3.7)    | 0.414 | 54/1285 (4.2)   |
| Mechanical ventilation ≥ 7 days (%)             | 67/644 (10.4)   | 88/641 (13.7)   | 0.067 | 155/1285 (12.1) |
| Patent ductus arteriosus (%)                    | 132/644 (20.5)  | 111/641 (17.3)  | 0.146 | 243/1285 (18.9) |
| Caesarean section (%)                           | 384/644 (59.6)  | 401/641 (62.6)  | 0.281 | 785/1285 (61.1) |
| Premature rupture membranes (%)                 | 234/644 (36.3)  | 227/641 (35.4)  | 0.730 | 461/1285 (35.9) |
| Hypertension of pregnancy (%)                   | 155/644 (24.1)  | 181/641 (28.2)  | 0.089 | 336/1285 (26.1) |
| First feeding (days), mean ± SD                 | 4.3 ± 2.1       | 4.5 ± 2.2       | 0.324 | 4.4 ± 2.2       |
| Formula milk feeding (%)                        | 181/644 (28.1)  | 166/641 (25.9)  | 0.374 | 347/1285 (27.0) |

**Table 2 rhEPO protected very preterm infants against NEC**

| NEC | Control n/total (%) | rhEPO n/total (%) | \( p \)-value | Total n/total (%) |
|-----|---------------------|-------------------|--------------|------------------|
| Stage I | 75/644 (11.6)    | 59/641 (9.2)       | 0.152     | 134/1285 (10.4)  |
| Stage II | 25/644 (3.9)     | 15/641 (2.3)       | 0.112     | 40/1285 (3.1)   |
| Stage III | 10/644 (1.6)    | 4/641 (0.6)        | 0.109     | 14/1285 (1.1)   |
| Stage II and III | 35/644 (5.4) | 19/641 (3.0)       | 0.027    | 54/1285 (4.2)   |
| Stage I, II and III | 110/644 (17.1) | 77/641 (12.0)       | 0.010    | 187/1285 (14.6) |

**Table 3 Anemia and thrombocytopenia in confirmed NEC**

|                        | Control n = 35 | rhEPO n = 19 | \( p \)-value | Total n = 54 |
|------------------------|----------------|--------------|--------------|--------------|
| Days at diagnosis with NEC, d | 12.6 ± 11.5 | 10.7 ± 11.3 | 0.555 | 11.9 ± 11.4 |
| Gestational age at diagnosis with NEC, w | 31.4 ± 1.9 | 31.5 ± 2.6 | 0.864 | 31.4 ± 2.1 |
| Anemia before NEC, n/total (%) | 24/35 (68.6%) | 11/19 (57.9%) | 0.553 | 35/54 (64.8%) |
| Hb < 90 g/l before NEC, n/total (%) | 8/35 (22.9%) | 4/19 (21.1%) | 0.878 | 12/54 (22.2%) |
| RBC transfusion before NEC, n/total (%) | 8/35 (22.9%) | 6/19 (31.6%) | 0.528 | 14/54 (25.9%) |
| Time between transfusion and NEC, hours | 29.8 ± 68.0 | 49.8 ± 89.7 | 0.361 | 36.8 ± 76.1 |
| Number of RBC transfusions | 2.7 ± 1.0 | 1.2 ± 0.4 | 0.004 | 2.0 ± 1.1 |
| Thrombocytopenia, n/total (%) | 15/35 (42.9) | 10/19 (52.6) | 0.573 | 25/54 (46.3) |
| Platelet count \((\times 10^9/l)\) | 135 ± 93 | 103 ± 73 | 0.204 | 123 ± 87 |
transfusion before NEC was not significantly different in the control (8/35, 22.9%) and rhEPO treatment group (6/19, 31.6%, \( p = 0.528 \)), nor was the time from RBC transfusion to diagnosed NEC (29.8 ± 68.0 h in the control group and 49.8 ± 89.7 h in the rhEPO group; \( p = 0.361 \)). However, rhEPO treatment significantly decreased the number of RBC transfusion in confirmed NEC (2.7 ± 1.0 in control vs. 1.2 ± 0.4 in rhEPO group, \( p = 0.004 \)).

The platelet count in the diagnosed NEC infants was 135 ± 93 \( \times 10^9 \)/l in the control group and 103 ± 73 \( \times 10^9 \)/l in the rhEPO group (\( p = 0.204 \)), and the incidence of thrombocytopenia was also not significantly different between controls (15/35, 42.9%) and the rhEPO treatment group (10/19, 52.6%, \( p = 0.573 \)) (Table 3). Furthermore, the effect of rhEPO against confirmed NEC (stage II and III) was observed in preterm infants with gestation age < 28w (\( p < 0.05 \)) with an interaction \( p \)-value of 0.013, but not for the infants with gestation age 28–29+7/7w or 30–32w, (\( p > 0.05 \)). There were no interaction effect on rhEPO against confirmed NEC of different birth weights, delivery modes, mechanical ventilation, serum hemoglobin, sex, or Apgar scores at 1 min and 5 min (interaction \( p > 0.05 \) for all) (Table 5).

### Discussion

NEC is one of the most severe complications in preterm neonates and is associated with high morbidity and mortality. NEC often occurs in outbreaks, suggesting the involvement of infectious agents [24, 25], and it proceeds through a cascade of events before any effective treatment can be applied. Therefore, the development of preventive strategies against NEC is of utmost importance.

Table 4 Subgroup analysis the effect of rhEPO on all stages NEC

|                      | Control n/total (%) | rhEPO n/total (%) | \( p \)-value | Relative risk [95% CI] | Interaction \( p \) | Total n/total (%) |
|----------------------|---------------------|-------------------|--------------|------------------------|-------------------|------------------|
| **Gestation age**    |                     |                   |              |                        |                   |                  |
| < 28w                | 11/53 (20.8)        | 8/57 (14.0)       | 0.352        | 0.623 [0.229–1.694]    | 0.581             | 19/110 (17.3)    |
| 28–29+7/7w          | 49/258 (19.0)       | 33/288 (11.5)     | 0.014        | 0.552 [0.342–0.890]    |                   | 82/546 (15.0)    |
| 30–32w               | 50/333 (15.0)       | 36/296 (12.2)     | 0.299        | 0.784 [0.495–1.242]    |                   | 86/629 (13.7)    |
| **Birth weight**     |                     |                   |              |                        |                   |                  |
| < 1000 g             | 18/54 (33.3)        | 5/50 (10.0)       | 0.004        | 0.222 [0.075–0.657]    |                   | 23/104 (22.1)    |
| 1000–1499 g          | 70/432 (16.2)       | 54/462 (11.7)     | 0.051        | 0.684 [0.467–1.003]    |                   | 124/894 (13.9)   |
| ≥ 1500 g             | 22/158 (13.9)       | 18/129 (14.0)     | 0.994        | 1.002 [0.512–1.962]    | 0.060             | 40/287 (13.9)    |
| **Delivery mode**    |                     |                   |              |                        |                   |                  |
| Vaginal delivery     | 39/260 (15.0)       | 26/240 (1.7)      | 0.166        | 0.688 [0.405–1.170]    |                   | 65/500 (13.0)    |
| Caesarean            | 71/384 (18.5)       | 51/401 (12.7)     | 0.026        | 0.642 [0.435–0.949]    | 0.837             | 122/785 (15.5)   |
| **Gender**           |                     |                   |              |                        |                   |                  |
| Girl                 | 41/259 (15.8)       | 27/267 (10.1)     | 0.051        | 0.598 [0.336–1.051]    | 0.552             | 68/526 (12.9)    |
| Boy                  | 69/385 (17.9)       | 50/374 (13.4)     | 0.085        | 0.707 [0.476–1.050]    | 0.616             | 119/759 (15.7)   |
| **Mechanical ventilation** |                 |                   |              |                        |                   |                  |
| < 7 days             | 85/577 (14.7)       | 62/553 (11.2)     | 0.079        | 0.731 [0.515–1.038]    |                   | 147/1130 (13.0)  |
| ≥ 7 days             | 25/67 (37.3)        | 15/88 (17.0)      | 0.004        | 0.345 [0.164–0.727]    | 0.072             | 40/155 (25.8)    |
| **1 min Apgar score**|                     |                   |              |                        |                   |                  |
| > 3                  | 105/614 (17.1)      | 76/617 (12.3)     | 0.018        | 0.681 [0.495–0.937]    | 0.681             | 181/1231 (14.7)  |
| ≤ 3                  | 5/30 (16.7)         | 1/24 (4.2)        | 0.146        | 0.217 [0.024–2.003]    | 0.299             | 6/54 (11.1)      |
| **5 min Apgar score**|                     |                   |              |                        |                   |                  |
| > 5                  | 104/622 (17.3)      | 74/608 (12.2)     | 0.028        | 0.690 [0.500–0.952]    | 0.690             | 178/1230 (14.5)  |
| ≤ 5                  | 6/22 (27.3)         | 3/33 (9.1)        | 0.134        | 0.267 [0.059–1.211]    | 0.012             | 9/55 (16.4)      |
| Hemoglobin           |                     |                   |              |                        |                   |                  |
| ≥ 90 g/l             | 31/296 (10.5)       | 36/301 (12.0)     | 0.565        | 1.161 [0.698–1.933]    |                   | 67/597 (11.2)    |
| < 90 g/l             | 79/348 (22.7)       | 41/340 (12.1)     | 0.000        | 0.467 [0.309–0.705]    | 0.006             | 120/688 (17.4)   |
been hampered by small numbers of patients [13, 14], and the current study had a larger sample size than all similar previous studies of preterm infants. The results of this study strongly suggest that rhEPO is a potential promising therapeutic target for the prevention and/or treatment of NEC in very preterm infants.

Erythropoietin receptors have been observed on enterocytes in the developing human fetus and in human neonates [26, 27], and based on all of the work described below we speculate that rhEPO plays an important role against NEC in very preterm infants through its anti-inflammatory actions, by maintaining the integrity of the intestinal barrier, by inhibiting apoptosis, and by inhibiting oxidative stress. Animal models of NEC have suggested that EPO reduces NEC injury by reducing inflammatory reactions [28] and by maintaining the integrity of the intestinal barrier by preventing the loss of the tight junction protein ZO-1 and by normalizing other intestinal epithelial tight junction components [10]. In addition, EPO decreases both autophagy and apoptosis via the Akt/mTOR signaling pathway and the MAPK/ERK pathway, and thus it reduces intestinal mucosa injury from inflammation [11]. Studies also indicate that EPO reduces the occurrence of NEC in mice and rats by inhibiting the lipid peroxidation mediated by oxygen-free radicals [29] and the excessive production of nitric oxide [9, 30, 31], both of which are associated with the pathogenesis of NEC. In infants, rhEPO (200 IU/kg twice a week for a total of 1 week) reduced neonatal NEC injury by reducing inflammation [13]. Notably, a recent study reported that relatively high endogenous neonatal EPO concentrations in the blood are associated with increased risk of NEC requiring surgery [32], which seems to be in conflict with our results. However, such relatively increased endogenous EPO levels might be due to severe stress status in the infants leading to the stimulation of endogenous EPO production for self-protection, but the increased endogenous EPO levels are still too low to have a sufficiently protective effect to avoid surgery in these infants. Indeed, a recent study showed that endogenous

| Table 5 Subgroup analysis of the effect of rhEPO on confirmed NEC |
|---------------------------------------------------------------|
| Control | rhEPO | p-value | Relative risk [95% CI] | Interaction | Total |
|----------|--------|---------|------------------------|------------|-------|
| n/total (%) | n/total (%) | p-value | p | p | n/total (%) |
| **Gestation age** | | | | | |
| <28 w | 9/53 (17.0) | 2/57 (3.5) | 0.019 | 0.178 [0.037–0.865] | 11/110 (10.0) |
| 28–296/7 w | 14/258 (5.4) | 7/288 (2.4) | 0.069 | 0.434 [0.172–1.093] | 21/546 (3.8) |
| 30–32 w | 12/333 (3.6) | 10/296 (3.4) | 0.878 | 0.935 [0.398–2.198] | 22/629 (3.5) |
| **Birth weight** | | | | | |
| <1000 g | 12/54 (22.2) | 2/50 (4.0) | 0.007 | 0.146 [0.031–0.689] | 14/104 (13.5) |
| 1000–1499 g | 19/432 (4.4) | 10/462 (2.2) | 0.060 | 0.481 [0.221–1.046] | 29/894 (3.2) |
| ≥1500 g | 4/158 (2.5) | 7/129 (5.4) | 0.204 | 2.209 [0.632–7.720] | 0.142 | 11/287 (3.8) |
| **Delivery mode** | | | | | |
| Vaginal delivery | 15/260 (5.8) | 4/240 (1.7) | 0.017 | 0.277 [0.091–0.846] | 19/500 (3.8) |
| Caesarean | 20/364 (5.2) | 15/401 (3.7) | 0.319 | 0.707 [0.357–1.402] | 0.154 | 35/785 (4.5) |
| **Gender** | | | | | |
| Girl | 12/259 (4.6) | 4/267 (1.5) | 0.036 | 0.343 [0.108–1.091] | 16/526 (3.0) |
| Boy | 23/385 (6.0) | 15/374 (4.0) | 0.215 | 0.647 [0.332–1.260] | 0.267 | 38/759 (5.0) |
| **Mechanical ventilation** | | | | | |
| <7 days | 28/577 (4.9) | 17/553 (3.1) | 0.126 | 0.622 [0.336–1.149] | 45/1130 (4.0) |
| ≥7 days | 7/67 (10.4) | 2/88 (2.3) | 0.031 | 0.199 [0.040–0.993] | 0.181 | 9/155 (5.8) |
| **1 min Apgar score** | | | | | |
| >3 | 32/614 (5.2) | 19/617 (3.1) | 0.061 | 0.578 [0.324–1.031] | 51/1231 (4.1) |
| ≤3 | 3/30 (10.0) | 0/24 (0.0) | 0.111 | 0.900 [0.799–1.014] | 0.226 | 3/54 (5.6) |
| **5 min Apgar score** | | | | | |
| >5 | 34/622 (5.5) | 19/608 (3.1) | 0.060 | 0.558 [0.315–0.989] | 53/1320 (4.3) |
| ≤5 | 1/22 (4.5) | 0/33 (0.0) | 0.400 | 0.389 [0.278–0.543] | 0.053 | 1/55 (1.8) |
| **Hemoglobin** | | | | | |
| ≥90 g/l | 11/296 (3.7) | 7/301 (2.3) | 0.320 | 0.617 [0.236–1.614] | 18/597 (3.0) |
| <90 g/l | 24/348 (6.9) | 12/340 (3.5) | 0.047 | 0.494 [0.243–1.004] | 0.715 | 36/688 (5.2) |

Confirmed NEC means NEC stage II and III
EPO levels in the infants of the control group were very low compared to the concentrations resulting from exogenous rhEPO administration in the experimental group and in whom a protective effect was achieved [33]. Therefore, relatively high endogenous EPO levels in preterm infants might indicate a potentially severe status and that exogenous rhEPO administration is needed.

Subgroup analyses showed that rhEPO treatment significantly decreased the incidence of all stages NEC in preterm infants with Hb < 90 g/l. Multiple observational studies have reported an association between severe anemia and the development of NEC [34–36]. Anemia can impair splanchnic perfusion and increased risk of NEC [40, 43, 44]. The conflicting data regarding the role of anemia and RBC transfusion on the development of NEC remains unclear. Our data show that rhEPO could reduce the number of RBC transfusion in confirmed NEC, and that rhEPO could be beneficial for preterm infants against NEC, especially in those with Hb < 90 g/l.

Asphyxia is widely accepted as a risk factor for NEC. Hypoxia-reoxygenation could induce NEC in animal model [45]. Evidences show that EPO protects against NEC in newborn rats model induced by hypoxia-reoxygenation [10, 11, 38]. However, how does the severity of asphyxia affect the protective effect of EPO is unclear. In our study, rhEPO treatment significantly decreased the incidence of all stages NEC in preterm infants with 5 min Apgar score > 5, which indicates that severe asphyxia might induce irreversible damage to intestinal tract that beyond the preventive and therapeutic ability of rhEPO treatment.

Meanwhile, we found that rhEPO treatment significantly decreased the incidence of confirmed NEC (stage II and III) at a gestational age of <28w. It is reported that susceptibility to NEC is inversely related to gestational age [46, 47], and the immature intestinal barrier in lower gestational age infants might impact the effect of rhEPO therapy. rhEPO is also a neuroprotective drug, and its use in preterm infants has been heavily discussed in recent years [30]. Recently, one study [48] reported that there was no effect of rhEPO treatment (1000 U/kg for 6 doses after birth, then 400 U/kg three times per week up to 32 weeks of postmenstrual age) against NEC (all stages) in preterm infants of less than 28 weeks of gestational age. Similarly, we did not find a protective effect of rhEPO against all stages NEC in infants of less than 28 weeks of gestational age, but we did see an effect in infants of 28–29w/7 weeks of gestational age. However, our subgroup analysis showed that rhEPO has a preventive effect on the incidence of confirmed NEC in the infants of less than 28 weeks of gestational age, although the sample size of infants less than 28 weeks of gestational age in our study was much less than theirs (110 vs. 741 infants), but no subgroup analysis was available for the confirmed NEC cases from the published report [48]. Meanwhile, the high incidence of retinopathy of prematurity (ROP) (51% in the EPO group vs. 56% in the control group) in the published study indicates that the studied population or treatment protocol for the very preterm infants might have influenced the incidence of preterm complications and the therapeutic effect of rhEPO. A further study focusing on preterm infants of less than 28 weeks of gestational age as well as the effect of EPO on ROP is being performed (NCT02745990). Our current findings and the growing body of research on rhEPO suggest that rhEPO might be a promising drug for multiple complications in very preterm infants.

rhEPO was originally used at a low dose to prevent anemia in preterm infants, and it is now widely accepted as a routine application for all preterm infants as a substitute for blood transfusion [49–51]. Recent studies showed that rhEPO has multiple beneficial effects on preterm infants [18, 52, 53]. Our previous study with repeated administration of as low as 500 U/kg of rhEPO for 2 weeks showed not only neuroprotection, but also a reduced incidence of NEC and sepsis, although the mechanisms behind this are not fully understood [18]. In this study, even though rhEPO treatment reduced RBC transfusion and incidence of NEC, it did not do so in all of the preterm infants. This could be related to interpatient variability in rhEPO responsiveness, and a pharmacokinetics approach might be an option to optimize rhEPO treatment in preterm infants [15, 16].

There were some shortcomings in our study that need to be mentioned. First, the diagnosis of stage I NEC was not easily confirmed and was often confounded with feeding intolerance, we did not consider this in our primary outcome. Although there are several categories of biomarkers for NEC [54] such as inflammatory cytokines, gut-associated proteins, and microRNAs, none of them are specific for NEC. Second, exclusive breastfeeding has not yet been implemented in the four NICUs of our study, which might have affected the incidence of NEC to some extent. Third, the small sample size of confirmed NEC patients restricted the evaluation of long-term outcomes. Further data collection and follow-up to
1–2 years are ongoing. Fourth, the dose and treatment protocol of rhEPO was based on our previous study without further optimization according to pharmacokinetics/pharmacodynamics data in the study population.

Conclusions
To our knowledge, this is the first large-sample prospective study showing that low-dose rhEPO prevents NEC in very preterm infants with gestational age < 32 weeks. Repeated low-dose rhEPO treatment reduced the risk of NEC compared with controls and without obvious adverse effects. This indicates that prophylactic early rhEPO treatment has multiple beneficial effects in very preterm infants and that rhEPO could be recommended for infants at risk of NEC. Whether such treatment improves long-term outcomes of NEC patients remains to be determined.

Abbreviations
Hb: Hemoglobin; NEC: Necrotizing enterocolitis; NICU: Neonatal intensive care unit; rhEPO: Recombinant human erythropoietin; RBC: Red blood cell.

Acknowledgements
We would like to thank all the infants and their parents of this study and the clinical staff at the Department of Neonatology of the First Affiliated Hospital, Third Affiliated Hospital, Children’s Hospital of Zhengzhou University and Department of Neonatology of Women and Children Health Care Center of Luoyang.

Authors’ contributions
YW and JS collected data, carried out the initial analyses, drafted the initial manuscript, and reviewed and revised the manuscript. HS, FX, KL, CN, XZ, XP, LX, ZS, XY, SZ, and YZ communicated with parents for consent and collected data. WK, LQ, WZ, XC, and XW conceived and designed the study and reviewed and revised the manuscript. CZ conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors agreed to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Funding
This study was supported by the National Key Research and Development Program of China (2018YFC1004604), the Department of Science and Technology of Henan Province of China (134200510023, 171100310200), the Swedish Research Council (2018-02267). Open access funding provided by University of Gothenburg.

Availability of data and materials
The datasets used and/or analyzed during the current study are included in this published article.

Ethics approval and consent to participate
This study protocol was approved by the Ethics Committee of Zhengzhou University and Henan Medical Academy (201201002).

Consent for publication
Not applicable.

Competing interest
The authors declare that they have no competing interests.

Author details
1 Henan Key Laboratory of Child Brain Injury, Department of Neonatology, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 2 Department of Neonatology, Children’s Hospital of Zhengzhou University, Zhengzhou 450018, China. 3 Department of Neonatology, Women and Children Health Care Center of Luoyang, Luoyang 471000, China. 4 Department of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 5 Department of Pediatrics, Children’s Hospital of Fudan University, Shanghai, China. 6 Center of Perinatal Medicine and Health, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden. 7 Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden. 8 Department of Women’s and Children’s Health, Karolinska Institutet, 17176 Stockholm, Sweden.

Received: 20 May 2020 Accepted: 26 July 2020

Published online: 08 August 2020

References
1. Battersby C, Santhalingam T, Costelec K, Modi N. Incidence of neonatal necrotising enterocolitis in high-income countries: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2018;103(2):F182–9.
2. Kastenberg ZJ, Lee HC, Proft J, Gould JB, Sylvester KG. Effect of deregionalized care on mortality in very low-birth-weight infants with necrotizing enterocolitis. JAMA Pediatr. 2015;169(1):26–32.
3. Hinzler SR, Kendrick DE, Stoll BL, Vohr BR, Fanaroff AA, Donovan EF, et al. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics. 2005;115(3):696–703.
4. Chawla S, Natarajan G, Shankaran S, Pappas A, Stoll BL, Carlo WA, et al. Association of neurodevelopmental outcomes and neonatal morbidities of extremely premature infants with differential exposure to antenatal steroids. JAMA Pediatr. 2016;170(12):1164–72.
5. Austran CA, Kellman BP, Kim JH, Asztalos E, Blood AB, Spence ECH, et al. Human milk oligosaccharide composition predicts risk of necrotising enterocolitis in preterm infants. Gut. 2018;67(6):1064–70.
6. Costelec K, Hardy P, Juszczak E, Wilks M, Millar MR. Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet (London, England). 2016;387(10019):649–60.
7. Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2017;6:CD007137.
8. Juul SE, Pet GC. Erythropoietin and neonatal neuroprotection. Clin Perinatal. 2015;42(3):469–81.
9. Kumral A, Baskin H, Duman N, Yilmaz O, Tati M, Ozer E, et al. Erythropoietin protects against necrotizing enterocolitis of newborn rats by inhibiting nitric oxide formation. Biol Neonate. 2003;84(4):325–9.
10. Shiou SR, Yu Y, Chen S, Ciancio MJ, Petrof EO, Sun J, et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. J Biol Chem. 2011;286(4):12123–32.
11. Yu Y, Shiou SR, Guo Y, Lu L, Westerhoff M, Sun J, et al. Erythropoietin protects epithelial cells from excessive autophagy and apoptosis in experimental neonatal necrotizing enterocolitis. PLoS ONE. 2013;8(7):e69620.
12. Ledbetter DJ, Juul SE. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg. 2000;35(2):178–82.
13. Qi W, Shen Q, Zhang L, Han LP, Wang S. Study on the inflammatory inter- vention of erythropoietin on NEC. Exp Ther Med. 2016;11(6):2221–4.
14. El-Ganzoury MM, Awad HA, El-Farrash RA, El-Gammasy TM, Ismail EA, Mohamed HE, et al. Enteral granulocyte-colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. J Pediatr. 2014;165(8):1140–1145.e1.
15. Rosebraugh MR, Widness JA, Nalbant D, Cress GA, Veng-Pedersen P. Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants. Pediatr Res. 2014;75(2):336–42.
16. D’Cunha R, Schmidt R, Widness JA, Mock DM, Yan X, Cress GA, et al. Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens. Eur J Pharm Sci. 2019;138:105013.
17. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122(2):383–91.

18. Song J, Sun H, Fu F, Kang W, Gao L, Guo J, et al. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol. 2016;80(1):124–34.

19. Whyte RK, Jefferys AL, Newborn C, Canadian Paediatric Society F. Red blood cell transfusion in newborns. Paediatr Child Health. 2014;19(4):213–22.

20. Wiedmeier SE, Henry E, Sola-Visner MC, Christensen RD. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. J Perinatol. 2009;29(2):130–6.

21. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1–7.

22. Lambert DK, Christensen RD, Baer VL, Henry E, Gordon PV, Besner GE, et al. Fulminant necrotizing enterocolitis in a multihospital healthcare system. J Perinatol. 2012;32(3):194–8.

23. Fernandez-Carrocera LA, Solis-Herrera A, Cabanillas-Ayon M, Gallardo-Sarmiento RB, Garcia-Perez CS, Montano-Rodriguez R, et al. Double-blind, randomised clinical assay to evaluate the efficacy of probiotics in preterm newborns weighing less than 1500 g in the prevention of necrotising enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2013;98(1):F5–9.

24. Boccia D, Stolfi I, Liana S, Moro ML. Nosocomial necrotising enterocolitis outbreaks: epidemiology and control measures. Eur J Pediatr. 2001;160(6):385–91.

25. Meirizen-Derr J, Morrow AL, Hornung RW, Donovan EF; Dietrich KN, Supco PA. Epidemiology of necrotizing enterocolitis temporal clustering in two neonatology practices. J Pediatr. 2009;154(5):666–61.

26. Juul SE, Joyce AE, Zhao Y, Ledbetter DJ. Why is erythropoietin present in human milk? Studies of erythropoietin receptor on enterocytes of newborns and neonates. Pediatr Res. 1999;46(3):263–8.

27. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Human Dev. 1996;52(3):235–49.

28. Nathakumar N, Meng D, Goldstein AM, Zhu W, Lu L, Uauy R, et al. The association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA. 2019;321(4):380–6.

29. Seikku L, Rahkonen L, Tikkanen M, Hamalainen E, Rahkonen P, Andersson M, et al. The role of early high-dose recombinant erythropoietin for neuroprotection in preterm infants. J Perinatol. 2015;35(9):676–83.

30. Akisu M, Kullahcioglu Girgin F, Baka M, Husseyinov A, Kultursay N. The role of early high-dose recombinant erythropoietin in the developing human fetus. Early Human Dev. 2011;17(1):52–7.

31. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. N Engl J Med. 2020;382(3):233–43.

32. Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. JAMA. 2020;323(6):529–40.

33. Caplan MS, Hedlund E, Adler L, Huseh WR. Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis. Pediatric pathology. 1994;14(16):1071–28.

34. Blau J, Calo JM, Dozor D, Sutton M, Alpan G, La Gamma EF. Transfusion-related acute gastrointestinal injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. J Pediatr. 2011;158(3):403–9.

35. Yee WH, Soraisham AS, Shah VS, Aziz K, Yoon W, Lee SK. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. Pediatrics. 2012;129(2):e298–304.

36. Juul SE, Comstock BA, Wadhawan R, Mayock DE, Courtney SE, Robinson T, et al. A randomized trial of erythropoietin for neuroprotection in preterm infants. N Engl J Med. 2020;382(3):233–43.

37. Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, Fuller J, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics. 2014;133(6):1023–30.

38. Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics. 2009;124(4):e681–7.

39. Ahmara SW, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2020;265.

40. Bui KCT, Kim R, Abbasi A, Nguyen M, Villoso MF, Chen Q. Erythropoietin treatment is associated with a reduction in moderate to severe bronchopulmonary dysplasia in preterm infants: a regional retrospective study. Early Human Dev. 2019;137:104831.

41. Leuchter RH, Gui L, Poncet A, Hagnann C, Lodygensky GA, Martin E, et al. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA. 2014;312(8):817–24.

42. Ng PC. An update on biomarkers of necrotizing enterocolitis. Semin Fetal Neonatal Med. 2018;23(6):380–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.